Not Signed In -
Baclofen Disintegrating Tablets |
Lioresal Disintegrating Tablet |
Clinical Trial: Pilot Study of the Effect of Baclofen and Bromocriptine on Luteinizing Hormone Secretion in Pubertal Children
This study has been completed.
|
Purpose
OBJECTIVES: I. Evaluate the effect of bromocriptine on luteinizing hormone (LH) secretion by suppression of prolactin and stimulation of dopaminergic receptors in early pubertal boys and girls. II. Evaluate the effect of baclofen on LH secretion by stimulation of gamma-aminobutyric acid receptors in early pubertal boys and girls.
| Condition |
|---|
| Growth Disorders |
MedlinePlus related topics: Growth Disorders
Study Type: Observational
Study Design: Screening
Expected Total Enrollment: 4
Study start: June 1995
PROTOCOL OUTLINE: Participants receive bromocriptine or baclofen followed by nocturnal measurements of luteinizing hormone, growth hormone, and sex steroids. Pituitary reserve is evaluated with the administration of gonadotropin-releasing hormone, and in children undergoing assessment of short stature, standard provocative stimuli.
Eligibility
Ages Eligible for Study: up to 18 Years, Genders Eligible for Study: Both
Criteria
- Short stature and/or constitutional growth delay
- No epilepsy or risk of epilepsy
Location Information
Carol M. Foster, Study Chair, University of Michigan
More Information
Record last reviewed: December 2001
Last Updated: October 13, 2004
Record first received: February 24, 2000
ClinicalTrials.gov Identifier: NCT00004793
Health Authority: United States: Federal Government
ClinicalTrials.gov processed this record on 2005-04-08
Source: ClinicalTrials.gov
Cache Date: April 9, 2005
Resources
- Baclofen Disintegrating Tablets (Drug Digest)
- Lioresal Disintegrating Tablet (Drug Digest)
email this page
print this page
bookmark this page
feedback on this page
